ERBB2 and breast cancer: Lapatinib was approved by the US Food and Drug Administration (FDA) for the treatment of HER2+ breast cancer in combination with letrozole (Johnston et al., 2009) or capecitabine (Geyer et al., 2006) and shows promise when combined with trastuzumab (de Azambuja et al., 2014).